Header Image
Subclinical ADHD

Subclinical ADHD

Subclinical ADHD means that ADHD symptoms are present, but the threshold required for a diagnosis according to DSM or ICD has not been reached. Subclinical ADHD is not “non-existent ADHD”. It is ADHD that is more difficult to treat if the person with ADHD is suffering from it.

Since ADHD is not categorical but dimensional and, moreover, the degree of symptoms can fluctuate within a certain range even in the case of lifelong ADHD (“fluctuating ADHD” in 10 to 15 % of people with ADHD1 ), it makes sense to take subclinical ADHD seriously and to document the diagnosis.

Differentiating subclinical ADHD from late-onset ADHD
Sometimes ADHD becomes “subclinical” simply because, contrary to the DSM requirement, no occurrence of several symptoms before the age of 12 can be documented or retrospectively (= in retrospect) determined. If in such cases the number of symptoms exceeds the threshold value at the time of diagnosis and the other secondary requirements of the DSM or ICD are also met, it is not subclinical ADHD, but late-onset ADHD.
In a study of 7 to 9-year-old children with subclinical psychiatric disorders, 37% developed a full-blown Disorder after 3 years.2 The people with ADHD in this study had neither subclinical nor late-onset ADHD, but normal ADHD according to the DSM 5 criteria.
Unfortunately, the term late-onset ADHD is also used by many studies for cases in which individual symptoms were already present up to the age of 6 years (DSM IV) or 11 years (DSM 5) and only no full-blown ADHD was present. If a lack of a full picture up to this age is (in our opinion incorrectly) referred to as late-onset ADHD, there would need to be a different term to designate ADHD in which no symptoms or only one symptom was present up to the age of 6 (DSM IV) or 11 (DSM 5). More on this under Late-Onset ADHD: late-onset or late-diagnosed ADHD?

Subclinical ADHD is present if all DSM or IDC criteria are met with the exception of the number of symptoms at the time of diagnosis.
The updated European consensus on the treatment and diagnosis of ADHD from 2018 points out that studies are now available according to which, from a scientific point of view, a cut-off of 4 symptoms in adults would be more correct for a correct ADHD diagnosis.345

How it can be justified to withhold medical or psychotherapeutic help from people who have the same severity of symptoms and the same suffering as others, for whom, for example, only individual symptoms appeared or were documented early enough, is beyond our understanding.
If no other disorder can better explain the problems, off-label treatment is medically indicated. Unfortunately, we repeatedly experience a financial office-like attitude on the part of practitioners to deny such people with ADHD any treatment. This happens far too often to speak of individual cases.
It is cynical to deny people help just because medicine does not have a suitably named drawer for their actual problems. Medicine has to use people’s suffering as its primary yardstick. Since even subclinical ADHD is associated with increased suicide rates, comorbidity rates and suffering, denying medical or psychotherapeutic help is a liability case. Statistical and diagnostic manuals serve as points of reference and orientation as well as billing figures for health insurance companies. However, they are no justification for failure to provide assistance.

Whether a person suffers does not depend on whether DSM or ICD have a name for it. The fact that the 5th version of the DSM and the 11th version of the ICD exist proves that the knowledge about existing disorders is changing. The disorders themselves have always existed and continue to exist independently of this. A person does not begin to suffer because they receive a diagnosis, because DSM 5 has raised the age limit for the presence of symptoms from under 7 years to under 12 years. With the change in DSM 5 criteria, 21% of children with ADHD were diagnosed with ADHD who had been labeled subclinical under DSM IV because their first symptoms appeared between the ages of 7 and 11.6 This has not changed the way these children suffer from their symptoms. DSM 5 has merely made it easier to include the treatment of these people with ADHD under the correct term and to be able to bill this treatment more easily to health insurance companies.

Even if the problems and suffering of subclinical ADHD are not quite as drastic as those of clinical ADHD, this does not justify leaving these people alone with their problems. The decisive criterion can only be the suffering, not a definition in a statistical-diagnostic manual or a billing mode of a health insurance company.
This does not mean that assistance below the legally defined threshold should be provided on a cash basis. It may be doubtful whether the legal regulations on this are appropriate or economically wise, but they are completely disconnected from the ethical question of whether a person is entitled to medical or psychological help.

Some studies have attempted to measure the prevalence of subclinical ADHD. This is inherently complicated by the fact that no clear criteria have been established for subclinical ADHD.
More on this at Prevalence of subclinical ADHD in the article Frequency of ADHD (prevalence) In the chapter Diagnostics.

Subclinical ADHD is also associated with symptomatic and social limitations as well as increased comorbidities 78

  • Suicide
    • Suicidal plans were 54 times more common in people with ADHD and 18 times more common in subclinical ADHD than in people without ADHD. Suicidal thoughts were 12.8 times as common in those with ADHD and 8.3 times as common in those with subclinical ADHD as in those without ADHD9
  • Addiction
    • Cannabis abuse was as high in subclinical ADHD as in clinical ADHD and significantly higher than in non-affected individuals10
    • Internet addiction was almost as high in subclinical ADHD as in clinical ADHD10
  • Sleep
    • Sleep quality was significantly worse in subclinical ADHD than in non-affected people, although not as bad as in clinical ADHD10
  • Quality of LIfe
    • Social quality of life was almost as severely impaired with subclinical ADHD as with clinical ADHD10
    • Quality of life for subclinical ADHD was in the middle between ADHD and non-affected people10
  • Cognition
    • In subclinical ADHD, 23% had impairments in 3 or more cognitive domains, compared to 4% to 6% in non-affected individuals11
  • Externalizing symptoms
    • Subclinical ADHD showed weaker externalizing symptoms than clinical ADHD, while internalizing symptoms were comparable.12 However, we also see this as a consequence of an overweighting of externalizing symptoms in the ADHD scales.
    • Subthreshold ADHD showed an increased risk of externalizing disorders and higher scores in eight CBCL scales (somatic complaints, anxiety/depression, social problems, attention problems, delinquent behavior, aggressive behavior, externalizing problems and overall behavior problems) compared to controls13
  • Social behavior
    • Subclinical ADHD, like clinical ADHD, is more likely to show impairment in recognizing social cues in facial expressions, resulting in impaired social functioning14
  • Education
    • Subclinical ADHD scored as poorly as ADHD on academic (reading and math) and non-academic (school engagement, attendance, peer bullying and parental expectations) outcomes15
  • Comorbidities
    • Subclinical ADHD showed significantly increased comorbidity16
  • Inattention
    • Subclinical ADHD showed increased inattention (4.34) compared to controls (0.33) or from unaffected twins of people with ADHD (0.44), while not reaching the levels of ADHD (7.33)17
  • Hyperactivity/impulsivity
    • Subclinical ADHD showed increased hyperactivity/impulsivity (2.73) compared to controls (0.17) or from unaffected twins of people with ADHD (0.43), not reaching the values of ADHD (5.99) 17

Lower impairments than in ADHD were found in subclinical ADHD for:

  • Executive functions
    • In adults with subclinical ADHD, executive functions were not impaired compared to controls16

Among very preterm infants, 66.4% showed subclinical ADHD (32.7% subclinical ADHD and 33.6% subclinical ADHD-C). This was 3.32 times the rate of non-preterm infants (20%).18
Subclinically elevated ADHD symptom scores were also associated with greater executive dysfunction (inhibitory self-control, flexibility, and emergent metacognition).
Subclinically elevated levels of inattentive ADHD were also associated with lower IQ and higher perinatal clinical risk (more days on mechanical ventilation and more days on parenteral nutrition).
Subclinically elevated levels of hyperactive ADHD symptoms were also associated with lower socioeconomic status.


  1. Van Meter AR, Sibley MH, Vandana P, Birmaher B, Fristad MA, Horwitz S, Youngstrom EA, Findling RL, Arnold LE. The stability and persistence of symptoms in childhood-onset ADHD. Eur Child Adolesc Psychiatry. 2023 Jun 4. doi: 10.1007/s00787-023-02235-3. PMID: 37270740.

  2. Esin IS, Turan B, Akıncı MA, Karabak M, Dursun OB (2020): Do we need to re-think on subthreshold childhood psychiatric cases? A follow-up study. Med Hypotheses. 2020 Jun;139:109697. doi: 10.1016/j.mehy.2020.109697. PMID: 32247189.

  3. Kooij, Bijlenga, Salerno, Jaeschke, Bitter, Balázs, Thome, Dom, Kasper, Filipe, Stes, Mohr, Leppämäki, Brugué, Bobes, Mccarthy, Richarte, Philipsen, Pehlivanidis, Niemela, Styr, Semerci, Bolea-Alamanac, Edvinsson, Baeyens, Wynchank, Sobanski, Philipsen, McNicholas, Caci, Mihailescu, Manor, Dobrescu, Krause, Fayyad, Ramos-Quiroga, Foeken, Rad, Adamou, Ohlmeier, Fitzgerald, Gill, Lensing, Mukaddes, Brudkiewicz, Gustafsson, Tania, Oswald, Carpentier, De Rossi, Delorme, Simoska, Pallanti, Young, Bejerot, Lehtonen, Kustow, Müller-Sedgwick, Hirvikoski, Pironti, Ginsberg, Félegeházy, Garcia-Portilla, Asherson (2018): Updated European Consensus Statement on diagnosis and treatment of adult ADHD, European Psychiatrie, European Psychiatry 56 (2019) 14–34, http://dx.doi.org/10.1016/j.eurpsy.2018.11.001, Seite 17

  4. Solanto, Wasserstein, Marks, Mitchell (2012): Diagnosis of ADHD in adults: what is the appropriate DSM-5 symptom threshold for hyperactivity-impulsivity? J Atten Disord. 2012 Nov;16(8):631-4. doi: 10.1177/1087054711416910.

  5. Kooij, Buitelaar, van den Oord, Furer, Rijnders, Hodiamont (2005): Internal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol Med. 2005 Jun;35(6):817-27.

  6. Biederman J, Fitzgerald M, Kirova AM, Woodworth KY, Biederman I, Faraone SV (2018): Further Evidence of Morbidity and Dysfunction Associated With Subsyndromal ADHD in Clinically Referred Children. J Clin Psychiatry. 2018 Aug 7;79(5):17m11870. doi: 10.4088/JCP.17m11870. PMID: 30086214.

  7. Hong SB, Dwyer D, Kim JW, Park EJ, Shin MS, Kim BN, Yoo HJ, Cho IH, Bhang SY, Hong YC, Pantelis C, Cho SC (2014): Subthreshold attention-deficit/hyperactivity disorder is associated with functional impairments across domains: a comprehensive analysis in a large-scale community study. Eur Child Adolesc Psychiatry. 2014 Aug;23(8):627-36. doi: 10.1007/s00787-013-0501-z. PMID: 24318039. n = 921

  8. He L, Zhao Y, Gong JX, Zhao L, Ma ZR, Xiong QW, Cai SZ, Yan XM (2024): Contrasting presentations of children with ADHD and subthreshold ADHD. Pediatr Res. 2024 Aug 24. doi: 10.1038/s41390-024-03502-y. PMID: 39179877.

  9. Oh Y, Kim Y, Ryu V (2024): Heightened suicidal risk in ADHD and subthreshold ADHD: Understanding the role of psychiatric comorbidities. Asian J Psychiatr. 2024 Dec;102:104277. doi: 10.1016/j.ajp.2024.104277. PMID: 39476752.

  10. Gostoli S, Raimondi G, Gremigni P, Rafanelli C (2024): Subclinical attention-deficit hyperactivity disorder symptoms and unhealthy lifestyle behaviours. BJPsych Open. 2024 Oct 3;10(5):e168. doi: 10.1192/bjo.2024.785. PMID: 39359149; PMCID: PMC11536216.

  11. Schiavone N, Virta M, Leppämäki S, Launes J, Vanninen R, Tuulio-Henriksson A, Järvinen I, Lehto E, Hokkanen L (2024): Childhood ADHD and subthreshold symptoms are associated with cognitive functioning at age 40-a cohort study on perinatal birth risks. Front Psychol. 2024 Aug 29;15:1393642. doi: 10.3389/fpsyg.2024.1393642. PMID: 39268376; PMCID: PMC11391087.

  12. Tang Y, Qiu S, Li H, Si F, Zhao M, Dong M, Pan M, Yue X, Liu L, Qian Q, Wang Y (2023): The Clinical Manifestation, Executive Dysfunction, and Caregiver Strain in Subthreshold Attention-Deficit/Hyperactivity Disorder. Psychiatry Investig. 2023 Sep;20(9):789-798. doi: 10.30773/pi.2023.0070. PMID: 37794660; PMCID: PMC10555518.

  13. Cho SC, Kim BN, Kim JW, Rohde LA, Hwang JW, Chungh DS, Shin MS, Lyoo IK, Go BJ, Lee SE, Kim HW (2009): Full syndrome and subthreshold attention-deficit/hyperactivity disorder in a Korean community sample: comorbidity and temperament findings. Eur Child Adolesc Psychiatry. 2009 Jul;18(7):447-57. doi: 10.1007/s00787-009-0755-7. PMID: 19205781. n = 2.493

  14. Staff AI, Luman M, van der Oord S, Bergwerff CE, van den Hoofdakker BJ, Oosterlaan J (2022): Facial emotion recognition impairment predicts social and emotional problems in children with (subthreshold) ADHD. Eur Child Adolesc Psychiatry. 2022 May;31(5):715-727. doi: 10.1007/s00787-020-01709-y. PMID: 33415471; PMCID: PMC9142461.

  15. Zendarski N, Guo S, Sciberras E, Efron D, Quach J, Winter L, Bisset M, Middeldorp CM, Coghill D (2022): Examining the Educational Gap for Children with ADHD and Subthreshold ADHD. J Atten Disord. 2022 Jan;26(2):282-295. doi: 10.1177/1087054720972790. PMID: 33317376.

  16. Schneidt A, Höhnle NM, Schönenberg M (2020): Cognitive and electrophysiological markers of adult full syndrome and subthreshold attention-deficit/hyperactivity disorder. J Psychiatr Res. 2020 Aug;127:80-86. doi: 10.1016/j.jpsychires.2020.05.004. PMID: 32502722.

  17. Jiang W, Duan K, Rootes-Murdy K, Hoekstra PJ, Hartman CA, Oosterlaan J, Heslenfeld D, Franke B, Buitelaar J, Arias-Vasquez A, Liu J, Turner JA (2020): Structural brain alterations and their association with cognitive function and symptoms in Attention-deficit/Hyperactivity Disorder families. Neuroimage Clin. 2020;27:102273. doi: 10.1016/j.nicl.2020.102273. PMID: 32387850; PMCID: PMC7210582.

  18. Montagna, Karolis, Batalle, Counsell, Rutherford, Arulkumaran, Happe, Edwards, Nosarti (2020): ADHD symptoms and their neurodevelopmental correlates in children born very preterm. PLoS One. 2020 Mar 3;15(3):e0224343. doi: 10.1371/journal.pone.0224343. PMID: 32126073; PMCID: PMC7053718. n = 119

Diese Seite wurde am 28.08.2025 zuletzt aktualisiert.